By
Jaclyn Jaeger2020-05-07T14:19:00
Alexion Pharmaceuticals said in a regulatory filing that it is nearing a $25 million settlement with the Securities and Exchange Commission concerning an investigation into the company’s compliance with the Foreign Corrupt Practices Act spanning various countries.
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
2020-07-02T15:26:00Z By Jaclyn Jaeger
Alexion Pharmaceuticals will pay $21 million to resolve SEC charges that it violated the books and records and internal accounting controls provisions of the FCPA concerning bribes made by subsidiaries to foreign government officials.
2015-11-06T14:00:00Z By Jaclyn Jaeger
Alexion Pharmaceuticals said this week in a securities filing that it is being investigated by the Department of Justice concerning potential violations of the Foreign Corrupt Practices Act. As previously disclosed, Alexion received a subpoena in May in connection with an investigation by the SEC’s Enforcement Division “requesting information related ...
2026-01-27T20:18:00Z By Jaclyn Jaeger
U.S. oil and gas companies strong-armed into participating in the nationalization of Venezuela’s oil industry decades ago now face government pressure of the opposite kind: Invest billions into rebuilding a dilapidated oil and gas infrastructure for a high-risk country that still owes billions in unsettled debts.
2026-01-22T17:32:00Z By Neil Hodge
Nick Ephgrave, director of the U.K.’s main anti-corruption enforcement agency, the Serious Fraud Office, will retire at the end of March—about halfway through his appointed five-year term. Experts say he leaves the agency in a lot better position than he joined it in September 2023.
2026-01-16T20:32:00Z By Oscar Gonzalez
The U.S. Federal Trade Commission finalized its order against General Motors and its OnStar subsidiary over the improper usage of geolocation and driving behavior data of drivers.
2026-01-16T17:49:00Z By Adrianne Appel
Kaiser Health affiliates have agreed to pay more than $556 million to settle allegations originally made by whistleblowers that they ignored compliance department warnings and unlawfully reworked diagnoses for Medicare patients in order to receive higher payments from the federal government.
Site powered by Webvision Cloud